Biopharmaceutical/Targeted Protein Degradation Therapeutics
Strategic Profile
Nurix utilizes an integrated discovery platform incorporating artificial intelligence and ligase expertise to support research activities. The company develops Degrader Antibody Conjugates (DACs) that combine the cell specificity of antibodies with the potency and selectivity of degraders. Recent significant funding of $250 million and recognition as a high-potential small cap stock indicate strong financial backing and market confidence.
Cyborg Score Rationale
With a $1.7B market capitalization and $84M trailing twelve-month revenue, Nurix demonstrates solid financial positioning. The company's multiple partnerships with major pharma companies and advanced clinical pipeline provide competitive advantages, though pre-commercial stage status and clinical trial risks moderate the rating.
Top Insights
Lead candidate Bexobrutideg (NX-5948) is in Phase 1B/2 trials targeting B-cell malignancies and autoimmune diseases.
Gilead Sciences extended its strategic collaboration research term for an additional two years with a $15 million extension fee and future milestone eligibility.
Nurix is identified as one of the best small cap stocks ready to explode in 2026.
Pipeline includes NX-5948 (BTK degrader), NX-2127 (BTK degrader), and NX-1607 (CBL-B inhibitor) across multiple clinical stages.
Named Competitors
Targeted Protein Degradation — Clinical-stage protein degradation therapeutics
Targeted Protein Degradation — E3 ligase modulators for drug discovery
Antibody-Drug Conjugates — Oncology-focused biopharmaceutical company
Immuno-oncology — Biopharmaceutical company in Seattle
Recent Developments
(December 2025) Presented positive Phase 1 trial data for Bexobrutideg in CLL patients at ASH Meeting
(October 2025) Closed $250 million registered offering of common stock
(October 2025) Reported new clinical data on NX-1607 at ESMO Congress
(November 2025) Appointed Roger Dansey, M.D. to board of directors
Open the full interactive Nurix Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.